| |
| Home |
| New Products |
| Contact us |
Human Soluble LOX-1ELISA Kit, Protein & Antibody
|
|
| New Monoclonal Antibodies were raised with human soluble LOX-1 recombinant derived from human cells. These highly specific monoclonal antobodies are against human soluble LOX-1.Bulk size are available for immunoassay development. | |
| Soluble LOX-1 (Human) ELISA Kit (SK00006-01) had been used by Dr. Akinnusi ME on following research paper Chest. 2011 Dec;140(6):1503-10 | |
Lectin-like oxidized low-density lipoprotein receptor-1 modulates endothelial apoptosis in obstructive sleep apnea. |
|
| BACKGROUND: Lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) is the major receptor for oxidized low-density lipoprotein in endothelial cells, and its expression is enhanced in proatherogenic settings. The objective of this study was to investigate the association between LOX-1 in freshly harvested human venous endothelial cells and apoptotic circulating endothelial cells in patients with obstructive sleep apnea (OSA). METHODS: We conducted a prospective, interventional study of 38 patients with newly diagnosed OSA free of disease and 12 healthy control subjects. Plasma LOX-1 (pLOX-1) levels were measured using a commercially available enzyme-linked immunosorbent assay. Protein expression of LOX-1 was quantified by immunofluorescence in freshly harvested venous endothelial cells before and after 8 weeks of continuous positive airway pressure (CPAP) therapy. Circulating apoptotic endothelial cells (CD146(+), CD45(-), and CD31(1)) were assessed concomitantly by flow cytometry. RESULTS: pLOX-1 levels were higher in subjects with OSA than in control subjects (326.9 ± 267.1 pg/mL and 141.1 ± 138.6 g/mL, respectively; P = .004). Patients with OSA showed a threefold increase in baseline endothelial expression of LOX-1 relative to control subjects. CPAP therapy resulted in a significant decrease in endothelial LOX-1 expression only in CPAP-adherent patients. Circulating apoptotic endothelial cells correlated directly with baseline expression of LOX-1 (R(2) = 0.32, P = .01) after adjustment for age, BMI, and waist to hip ratio. CONCLUSIONS: Increased expression of LOX-1 in vivo is associated with endothelial apoptosis. Adherence to CPAP therapy may reverse these derangements. | |
| Akinnusi ME, et al. Chest. 2011 Dec;140(6):1503-10 | |
Levels of Serum Soluble Lectin-like Oxidized LDL Receptor (sLOX-1) Predict Adverse Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease |
|
| Background: Oxidized LDL (oxLDL)
has been proposed as an independent biomarker of risk for adverse
cardiovascular (CV) outcomes. Lectin-like oxLDL receptor-1 (LOX-1) is
expressed in advanced plaques and activated platelets and may play a
role in plaque rupture; a soluble form (sLOX-1) can be measured in
serum. We aimed to define the prognostic value of these biomarkers in
patients with stable coronary artery disease (CAD). Methods: Levels of sLOX-1 and oxLDL [the latter using 2 different ELISAs: competitive (oxLDLc) and sandwich (oxLDLs)] were measured on baseline samples in 3791 patients enrolled in PEACE, a placebo-controlled trial of trandolapril vs placebo in patients w/stable CAD followed for 4.8 y for clinical outcomes. Multivariable Cox regression (limited access dataset, NHLBI) was used to adjust for age, sex, CV risk factors, lipid profile (apoB, apoA), lipid-lowering therapy, and treatment group. Results: The incidence of the composite of CV death, MI or stroke significantly increased across quartiles of each of the three biomarkers (Table). Both oxLDLc and oxLDLs levels were strongly correlated with apoB levels (r=0.64 and 0.53, respectively), whereas sLOX-1 was not (r=0.06). After adjustment for clinical factors, only sLOX-1 remained a significant predictor of CV death, MI or stroke (P=0.026 for trend; adj HR 1.41, 95% CI 1.03–1.94, P=0.015 for Q4 vs Q1). sLOX-1 was not strongly correlated with either high-sensitivity C-reactive protein (hs-CRP) or lipoprotein-associated phospholipase A2 (Lp-PLA2) (r=0.14 and r=0.05, respectively). After further adjustment for hs-CRP and Lp-PLA2, sLOX-1 remained a significant predictor of CV death, MI or stroke (P=0.038 for trend, adj HR 1.39, 95% CI 1.01–1.92, P=0.04 for Q4 vs Q1). Conclusion: In stable CAD, an elevated level of sLOX-1 predicts CV death, MI or stroke independent of clinical risk factors and other inflammatory biomarkers. Further studies are needed to determine the clinical utility of measuring sLOX-1. |
|
| Marwa A Sabe et al. Circulation. 2009;120:S452. | |
 |
|
 |
|
 |
Human
Soluble LOX-1 ELISA Code No.: SK00006-01 Size: 96 T Price: $360.00 USD Standard Range: 31-2000 pg/ml Sensitivity: 7.8 pg/ml sample Type: serum or plasma Dilution factor: 2 Intra-CV: 4-6% Inter-CV:8-10% Data Sheet: PDF |
| Mouse
Soluble LOX-1 ELISA Code No.: SK00006-03 Size: 96 T Price: $360.00 USD Standard Range: 31-2000 pg/ml Sensitivity: 7.8 pg/ml sample Type: serum or plasma Dilution factor: N/A Intra-CV: 4-6% Inter-CV:8-10% Data Sheet: PDF |
|
| Name | Code No. |
Size |
Price |
| Soluble LOX-1 (Human) ELISA Kit | 96 T |
360.00 |
|
| Soluble LOX-1 (Mouse) ELISA Kit | 96 T |
360.00 |
|
| Following Proteins May not be used for ELISA | |||
| Soluble LOX-1 (Human) Recombinant (HEK 293 derived) | 10 ug |
120.00 |
|
| Soluble LOX-1 (Human) Recombinant (HEK 293 derived) | 00006-06-20 |
20 ug |
200.00 |
| Anti Soluble LOX-1 (Human) Mab | A00006-02-100 |
100 ug |
220.00 |
| Anti Soluble LOX-1 (Human) Mab Biotinylated | A00006-02-50B |
50 ug |
320.00 |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-04-100 |
100 ug |
220.00 |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-05-100 |
100 ug |
220.00 |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-06-100 |
100 ug |
220.00 |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-07-100 |
100 ug |
220.00 |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-08-100 |
100 ug |
220.00 |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-09-100 |
100 ug |
220.00 |
| Anti Soluble LOX-1 (Human) Mab | A00006-02-1000 |
1 mg |
Inquire |
| Anti Soluble LOX-1 (Human) Mab Biotinylated | A00006-02-50B |
500 ug |
Inquire |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-04-1000 |
1 mg |
Inquire |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-05-1000 |
1 mg |
Inquire |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-06-1000 |
1 mg |
Inquire |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-07-1000 |
1 mg |
inquire |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-08-1000 |
1 mg |
Inquire |
| Anti Soluble LOX-1 (Human) Monoclonal Antibody | A00006-09-1000 |
1 mg |
Inquire |
|